Modality
Gene Therapy
MOA
PARPi
Target
CD47
Pathway
STING
NarcolepsyCKD
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
~Jan 2021
→ ~Apr 2022
NDA/BLA
~Jul 2022
→ ~Oct 2023
Approved
Jan 2024
→ Mar 2030
ApprovedCurrent
NCT08727615
2,367 pts·Narcolepsy
2024-01→2030-03·Active
2,367 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-03-284.0y awayPh3 Readout· Narcolepsy
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Active
Catalysts
Ph3 Readout
2030-03-28 · 4.0y away
Narcolepsy
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08727615 | Approved | Narcolepsy | Active | 2367 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 |